MX2010002178A - Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico. - Google Patents

Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico.

Info

Publication number
MX2010002178A
MX2010002178A MX2010002178A MX2010002178A MX2010002178A MX 2010002178 A MX2010002178 A MX 2010002178A MX 2010002178 A MX2010002178 A MX 2010002178A MX 2010002178 A MX2010002178 A MX 2010002178A MX 2010002178 A MX2010002178 A MX 2010002178A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
combination therapy
chemotherapeutic agent
antigenic peptide
potentiating
Prior art date
Application number
MX2010002178A
Other languages
English (en)
Spanish (es)
Inventor
Hiroki Yamaue
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2010002178A publication Critical patent/MX2010002178A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2010002178A 2007-08-24 2008-08-19 Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico. MX2010002178A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
MX2010002178A true MX2010002178A (es) 2010-03-18

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002178A MX2010002178A (es) 2007-08-24 2008-08-19 Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico.

Country Status (19)

Country Link
US (1) US8703713B2 (cg-RX-API-DMAC7.html)
EP (1) EP2195003A4 (cg-RX-API-DMAC7.html)
JP (1) JP5417667B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100047899A (cg-RX-API-DMAC7.html)
CN (1) CN101883577A (cg-RX-API-DMAC7.html)
AR (1) AR068020A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008292966C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0815726A2 (cg-RX-API-DMAC7.html)
CA (1) CA2697501A1 (cg-RX-API-DMAC7.html)
IL (1) IL204143A (cg-RX-API-DMAC7.html)
MX (1) MX2010002178A (cg-RX-API-DMAC7.html)
MY (1) MY160406A (cg-RX-API-DMAC7.html)
NZ (1) NZ583578A (cg-RX-API-DMAC7.html)
RU (1) RU2472522C2 (cg-RX-API-DMAC7.html)
SG (1) SG183770A1 (cg-RX-API-DMAC7.html)
TW (1) TWI436775B (cg-RX-API-DMAC7.html)
UA (1) UA100702C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009028150A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001580B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073620B (zh) 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
US20130149302A1 (en) * 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
DK3597742T3 (da) * 2014-10-09 2022-10-03 Univ Yamaguchi Car-udtrykkende vektor og car-udtrykkende t-celler
AU2015333728B2 (en) * 2014-10-14 2020-07-30 Riptide Bioscience, Inc. Peptide-based methods for treating pancreatic cancer
EP3626260A4 (en) * 2017-05-19 2021-05-19 Keio University PEPTIDE VACCINE AND PEPTIDE VACCINE COMPOSITION FOR CRANIAL NERVOUS DISEASE
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) * 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
WO1999040118A1 (en) 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CN103073620B (zh) * 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CN1960732A (zh) * 2004-06-03 2007-05-09 霍夫曼-拉罗奇有限公司 用吉西他滨和egfr－抑制剂治疗
JP5022911B2 (ja) 2004-12-17 2012-09-12 イーライ リリー アンド カンパニー ゲムシタビンのアミドプロドラック、組成物、及びそれらの使用
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2008099908A1 (ja) 2007-02-16 2008-08-21 Oncotherapy Science, Inc. 脈絡膜新生血管のワクチン療法

Also Published As

Publication number Publication date
CN101883577A (zh) 2010-11-10
US8703713B2 (en) 2014-04-22
ZA201001580B (en) 2011-02-23
UA100702C2 (ru) 2013-01-25
TWI436775B (zh) 2014-05-11
KR20100047899A (ko) 2010-05-10
NZ583578A (en) 2012-07-27
JP5417667B2 (ja) 2014-02-19
AU2008292966A1 (en) 2009-03-05
TW200914037A (en) 2009-04-01
JP2010536714A (ja) 2010-12-02
EP2195003A4 (en) 2011-07-06
WO2009028150A1 (en) 2009-03-05
IL204143A (en) 2013-04-30
EP2195003A1 (en) 2010-06-16
MY160406A (en) 2017-03-15
BRPI0815726A2 (pt) 2016-01-05
AU2008292966C1 (en) 2013-03-14
CA2697501A1 (en) 2009-03-05
US20110082088A1 (en) 2011-04-07
RU2010111139A (ru) 2011-09-27
AR068020A1 (es) 2009-10-28
AU2008292966B2 (en) 2012-07-19
SG183770A1 (en) 2012-09-27
RU2472522C2 (ru) 2013-01-20

Similar Documents

Publication Publication Date Title
MY160406A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
MX2013010770A (es) Tratamiento de tumores solidos.
NZ700759A (en) Combination therapy for treating cancer
GEP20166455B (en) Methods of administering pirfenidone therapy
PH12016502355B1 (en) Pharmaceutical composition
MX2014003180A (es) Metodos para tratar vhc.
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
MX2020001727A (es) Terapia de combinacion.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
TN2009000490A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
DK1971338T3 (da) Kombination af ZD6474 og pemetrexed
TN2009000136A1 (en) Sequential combination therapy
EP2294197A4 (en) HHIP1 PROTEIN VERSION AND METHOD AND USES THEREOF
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2007006557A (es) Metodos para utilizar intratecalmente una formulacion de temozolomida en el tratamiento de canceres.
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
DK1965801T3 (da) Kombination af azd2171 og pemetrexed

Legal Events

Date Code Title Description
FG Grant or registration